The immunomodulatory capacity of PTSO, demonstrated both in vitro and in vivo, was also linked to a notable increase in anti-tumor effector immune cells, particularly CD4+ and CD8+ T lymphocytes and NK cells. The gene discussed is CD4; the disease is neoplasm.